RyanPatrickKoppMD

Urology • Portland, OR

Surgical Oncology

Associate Professor, OHSU Department of Urology; Urologic Oncology, Portland VA Medical Center

Join to view full profile

Dr. Kopp is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kopp's full profile

Already have an account?

Office
3303 S Bond Ave
Ste CH10U
Portland, OR 97239
Phone+1 503-494-4779

Summary

Dr. Ryan Kopp is an urologist in Portland, OR and is affiliated with VA Portland Healthcare System. He received his medical degree from Indiana University School of Medicine, residency training at UC San Diego, and completed his urologic oncology fellowship at Memorial Sloan Kettering Cancer Center. He has held an appointment at Oregon Health & Science University and the VA Portland Healthcare System since 2015. He specializes in urologic oncology and is experienced in multidisciplinary care of genitourinary cancers (prostate, kidney, testicular, bladder), genetic research, cancer early detection, and clinical trials.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 2013 - 2015
University of California (San Diego) Medical CenterResidency, Urology, 2009 - 2013
University of California (San Diego) Medical CenterResidency, Surgery, 2007 - 2009
Indiana University School of MedicineClass of 2007

Certifications & Licensure

OR State Medical License 2015 - 2025
NY State Medical License 2012 - 2016
CA State Medical License 2009 - 2013
American Board of Urology Urology

Clinical Trials

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss Start of enrollment: 2024 May 31
Recruiting
Phase 2
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Start of enrollment: 2017 Feb 24
Active, not recruiting
Phase 3
Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants Start of enrollment: 2016 Jun 13
Terminated
Phase 1, Phase 2
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) Start of enrollment: 2019 Jun 13
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Multiplex imaging of localized prostate tumors reveals altered spatial organization of AR-positive cells in the microenvironment.
Çiğdem Ak, Zeynep Sayar, Guillaume Thibault, Erik A Burlingame, M J Kuykendall
Iscience. 2024-09-20
A Scaled Proteomic Discovery Study for Prostate Cancer Diagnostic Markers Using Proteographand Trapped Ion Mobility Mass Spectrometry.
Matthew E K Chang, Jane Lange, Jessie May Cartier, Travis W Moore, Sophia M Soriano
International Journal of Molecular Sciences. 2024-07-23
12 citations
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
Brant A Inman, Noah M Hahn, Kelly Stratton, Ryan Kopp, Alex Sankin
European Urology Oncology. 2023-06-01

Grant Support

Integration of Magnetic Resonance Imaging and Protein Biomarkers for Identification of Aggressive Prostate CancerCDMRP Prostate Cancer Research ProgramPresent